Q2 2026 saw robust growth in innovative products, offsetting generics declines, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow surged 31%, and the biosimilars portfolio expanded, while disciplined capital allocation and a Fitch upgrade strengthened the financial profile.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.